Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/37059
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMARTINS, Valquiria Carmo Alves
dc.contributor.authorCUNHA, Isabela Werneck
dc.contributor.authorFIGLIUOLO, Giuseppe
dc.contributor.authorRONDON, Heidy Halanna de Melo Farah
dc.contributor.authorSOUZA, Paloma Menezes de
dc.contributor.authorSILVA, Felipe Luz Torres
dc.contributor.authorSILVA, Guilherme Luz Torres
dc.contributor.authorBASTOS, Michele de Souza
dc.contributor.authorCASTRO, Daniel Barros de
dc.contributor.authorSANTANA, Monique Freire
dc.contributor.authorRAMASAWMY, Rajendranath
dc.contributor.authorLEVI, Jose Eduardo
dc.contributor.authorTORRES, Katia Luz
dc.date.accessioned2020-08-20T13:26:16Z-
dc.date.available2020-08-20T13:26:16Z-
dc.date.issued2020
dc.identifier.citationPLOS ONE, v.15, n.5, article ID e0232474, 18p, 2020
dc.identifier.issn1932-6203
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/37059-
dc.description.abstractBackground In Brazil, penile cancer (PC) is not uncommon. The highest incidence of PC is in the North and Northeast of the country. In addition to phimosis, the Human Papillomavirus (HPV) and Epstein-Baar Virus (EBV) infections are also related as risk factors for PC. The overexpression of p16(INK4a) is a surrogate sensitive marker of HPV infection in PC. Objectives To correlate p16(INK4a) overexpression and HPV infection status with EBV infection in a series of PC patients from the Amazon region. Methods Tumor tissues from 47 PC cases were analyzed for the presence of HPV and EBV DNA by PCR. All PC patients were diagnosed between 2013 and 2018 at a public reference cancer center hospital in Manaus, Amazonas-Brazil. HPV was genotyped using E7 HPV16/HPV18 type-specific real-time PCR and the PapilloCheck (R) HPV-Screening assay. p16INK4a expression was evaluated by immunohistochemistry using the automated Ventana (R) BenchMark Ultra. Results The mean age of patients at the time of diagnosis was 57.4 years +/- SD 17.8 ranging from 20 to 90 years old. Most of the patients (64%) came from rural areas of the Amazonas State. Thirty patients had phimosis (64%). Among the patients with phimosis, 43% (13/30) underwent circumcision, three during childhood and 10 in adulthood. 60% of the patients were smokers or ex-smokers. HPV infection was observed in 45% (21/47) of cases. HPV16 was detected in 13 patients (61%). Other HPV types detected were HPV 6, 11, 42, 51, 53, 68 and 44/55. EBV infection was observed in 30% (14/47) of the patients with PC. Co-infection with HPV and EBV was observed in 28% (6/21) cases. p16(INK4a) was only investigated in 26 samples. The p16(INK4a) overexpression was observed exclusively in HPV 16 positive cases and four HPV negative cases. In the survival analysis, the follow-up time was 35.4 months/patient. The mortality rate during the follow up time was 38%. Conclusions p16(INK4a) positivity presented a high correlation to HPV 16 DNA detection, reinforcing its use as a surrogate marker for HPV-driven cancers. Infection with EBV was quite frequent and its role in epithelial penile oncogenesis needs to be demonstrated.eng
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado do Amazonas-FAPEAM [021/2011-FAPEAM, 020/2013 FAPEAM, 05/2019 FAPEAM, 002./2008-FAPEAM]
dc.language.isoeng
dc.publisherPUBLIC LIBRARY SCIENCEeng
dc.relation.ispartofPlos One
dc.rightsopenAccesseng
dc.subject.otherepstein-barr-viruseng
dc.subject.otherhuman-papillomavirus dnaeng
dc.subject.othersquamous-cell carcinomaeng
dc.subject.otherin-situeng
dc.subject.otherprevalenceeng
dc.subject.otherclassificationeng
dc.subject.otherexpressioneng
dc.subject.othertumorseng
dc.subject.otherp53eng
dc.subject.otheramplificationeng
dc.titlePresence of HPV with overexpression of p16(INK4a) protein and EBV infection in penile cancer-A series of cases from Brazil Amazoneng
dc.typearticleeng
dc.rights.holderCopyright PUBLIC LIBRARY SCIENCEeng
dc.identifier.doi10.1371/journal.pone.0232474
dc.identifier.pmid32374757
dc.subject.wosMultidisciplinary Scienceseng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalMARTINS, Valquiria Carmo Alves:Fundacao Ctr Controle Oncol Estado Amazonas, Dept Educ & Res, Manaus, Amazonas, Brazil; Univ Fed Amazonas, Manaus, Amazonas, Brazil; Genom Hlth Surveillance Network Optimizat Assista, Manaus, Amazonas, Brazil
hcfmusp.author.externalCUNHA, Isabela Werneck:AC Camargo Canc Ctr, Dept Pathol, Sao Paulo, Brazil; Rede DOR Sao Luiz, Dept Pathol, Sao Paulo, Brazil
hcfmusp.author.externalFIGLIUOLO, Giuseppe:Fundacao Ctr Controle Oncol Estado Amazonas, Dept Educ & Res, Manaus, Amazonas, Brazil; Univ Estado Amazonas, Manaus, Amazonas, Brazil
hcfmusp.author.externalRONDON, Heidy Halanna de Melo Farah:Univ Fed Amazonas, Manaus, Amazonas, Brazil
hcfmusp.author.externalSOUZA, Paloma Menezes de:Univ Estado Amazonas, Manaus, Amazonas, Brazil
hcfmusp.author.externalSILVA, Felipe Luz Torres:Univ Fed Amazonas, Manaus, Amazonas, Brazil
hcfmusp.author.externalSILVA, Guilherme Luz Torres:Univ Estado Amazonas, Manaus, Amazonas, Brazil
hcfmusp.author.externalBASTOS, Michele de Souza:Fundacao Med Trop Heitor Vieira Dourado, Dept Virol, Manaus, Amazonas, Brazil
hcfmusp.author.externalCASTRO, Daniel Barros de:Genom Hlth Surveillance Network Optimizat Assista, Manaus, Amazonas, Brazil; Fundacao Vigilancia Saude Amazonas, Tech Advisory, Manaus, Amazonas, Brazil
hcfmusp.author.externalSANTANA, Monique Freire:Fundacao Ctr Controle Oncol Estado Amazonas, Dept Educ & Res, Manaus, Amazonas, Brazil; Fundacao Med Trop Heitor Vieira Dourado, Dept Virol, Manaus, Amazonas, Brazil
hcfmusp.author.externalRAMASAWMY, Rajendranath:Genom Hlth Surveillance Network Optimizat Assista, Manaus, Amazonas, Brazil; Fundacao Med Trop Heitor Vieira Dourado, Dept Virol, Manaus, Amazonas, Brazil; Univ Nilton Lins, Fac Med, Manaus, Amazonas, Brazil
hcfmusp.author.externalTORRES, Katia Luz:Fundacao Ctr Controle Oncol Estado Amazonas, Dept Educ & Res, Manaus, Amazonas, Brazil; Univ Fed Amazonas, Manaus, Amazonas, Brazil; Genom Hlth Surveillance Network Optimizat Assista, Manaus, Amazonas, Brazil
hcfmusp.description.articlenumbere0232474
hcfmusp.description.issue5
hcfmusp.description.volume15
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000537283500037
hcfmusp.origem.id2-s2.0-85084303474
hcfmusp.publisher.citySAN FRANCISCOeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAfonso LA, 2017, J MED VIROLOGYeng
hcfmusp.relation.referenceAfonso LA, 2012, MEM I OSWALDO CRUZ, V107, P18, DOI 10.1590/S0074-02762012000100003eng
hcfmusp.relation.referenceAlemany L, 2016, EUR UROL, V69, P953, DOI 10.1016/j.eururo.2015.12.007eng
hcfmusp.relation.referenceAlves G, 2004, CANCER LETT, V215, P79, DOI 10.1016/j.canlet.2004.04.025eng
hcfmusp.relation.referenceBackes DM, 2009, CANCER CAUSE CONTROL, V20, P449, DOI 10.1007/s10552-008-9276-9eng
hcfmusp.relation.referenceBARBOSA AD, 1984, REV SAUDE PUBL, V18, P429eng
hcfmusp.relation.referenceBethune G, 2012, UROLOGY, V79, P1092, DOI 10.1016/j.urology.2011.12.048eng
hcfmusp.relation.referenceBezerra ALR, 2001, CANCER, V91, P2315, DOI 10.1002/1097-0142(20010615)91:12<2315::AID-CNCR1263>3.3.CO;2-3eng
hcfmusp.relation.referenceBezerra SM, 2015, HUM PATHOL, V46, P532, DOI 10.1016/j.humpath.2014.12.004eng
hcfmusp.relation.referenceBleeker MCG, 2009, WORLD J UROL, V27, P141, DOI 10.1007/s00345-008-0302-zeng
hcfmusp.relation.referencede Sousa IDB, 2015, BMC UROL, V15, DOI 10.1186/s12894-015-0007-8eng
hcfmusp.relation.referenceCalmon MF, 2011, THESCIENTIFICWORLDJO, V11, P269, DOI 10.1100/tsw.2011.24eng
hcfmusp.relation.referenceChalya PL, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0482-0eng
hcfmusp.relation.referenceChipollini J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081777eng
hcfmusp.relation.referenceChristodoulidou M, 2015, CURR PROB CANCER, V39, P126, DOI 10.1016/j.currproblcancer.2015.03.010eng
hcfmusp.relation.referenceCubilla AL, 2011, AM J SURG PATHOL, V35, P253, DOI 10.1097/PAS.0b013e318203cdbaeng
hcfmusp.relation.referenceDaling JR, 2005, INT J CANCER, V116, P606, DOI 10.1002/ijc.21009eng
hcfmusp.relation.referencede Araujo LA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199557eng
hcfmusp.relation.referencede Lima MAP, 2006, REV BRASILEIRA CANCE, V52, P87eng
hcfmusp.relation.referenceDjajadiningrat RS, 2015, J UROLOGY, V193, P1245, DOI 10.1016/j.juro.2014.11.057eng
hcfmusp.relation.referencedo Couto TC, 2014, INT BRAZ J UROL, V40, P738, DOI 10.1590/S1677-5538.IBJU.2014.06.04eng
hcfmusp.relation.referenceDorfman S, 2006, TROP DOCT, V36, P232, DOI 10.1258/004947506778604896eng
hcfmusp.relation.referenceFavorito LA, 2008, INT BRAZ J UROL, V34, P587, DOI 10.1590/S1677-55382008000500007eng
hcfmusp.relation.referenceFerrandiz-Pulido C, 2015, GENE CHROMOSOME CANC, V54, P629, DOI 10.1002/gcc.22274eng
hcfmusp.relation.referenceFerreux E, 2003, J PATHOL, V201, P109, DOI 10.1002/path.1394eng
hcfmusp.relation.referenceFIGLIUOLO G, 2015, REV BRASILEIRA ONCOL, V11eng
hcfmusp.relation.referenceFonseca AGd, 2010, REV PAN AMAZ SAUDE, V1, P85eng
hcfmusp.relation.referenceGravitt PE, 2000, J CLIN MICROBIOL, V38, P357eng
hcfmusp.relation.referenceGuidry JT, 2017, VIRUS RES, V231, P139, DOI 10.1016/j.virusres.2016.11.002eng
hcfmusp.relation.referenceHeard I, 2016, J CLIN VIROL, V81, P6, DOI 10.1016/j.jcv.2016.05.004eng
hcfmusp.relation.referenceHernandez BY, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00009eng
hcfmusp.relation.referenceLAM KY, 1995, CANCER-AM CANCER SOC, V76, P658, DOI 10.1002/1097-0142(19950815)76:4<658::AID-CNCR2820760418>3.0.CO;2-Beng
hcfmusp.relation.referenceLarke NL, 2011, CANCER CAUSE CONTROL, V22, P1097, DOI 10.1007/s10552-011-9785-9eng
hcfmusp.relation.referenceLevi JE, 1998, INT J CANCER, V76, P779, DOI 10.1002/(SICI)1097-0215(19980610)76:6<779::AID-IJC1>3.3.CO;2-9eng
hcfmusp.relation.referenceMarkoulatos P, 2001, J CLIN MICROBIOL, V39, P4426, DOI 10.1128/JCM.39.12.4426-4432.2001eng
hcfmusp.relation.referenceMartinez-Bailon C, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4696-6eng
hcfmusp.relation.referenceMartins VD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205350eng
hcfmusp.relation.referenceMicali G, 2006, J AM ACAD DERMATOL, V54, P369, DOI 10.1016/j.jaad.2005.05.007eng
hcfmusp.relation.referenceMichels KB, 2009, LANCET, V374, P268, DOI 10.1016/S0140-6736(09)61247-2eng
hcfmusp.relation.referenceMiralles-Guri C, 2009, J CLIN PATHOLeng
hcfmusp.relation.referenceMoch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029eng
hcfmusp.relation.referenceCardona CEM, 2017, REV PANAM SALUD PUBL, V41, DOI 10.26633/RPSP.2017.117eng
hcfmusp.relation.referenceMosconi AM, 2005, CRIT REV ONCOL HEMAT, V53, P165, DOI 10.1016/j.critrevonc.2004.09.006eng
hcfmusp.relation.referenceMunoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641eng
hcfmusp.relation.referenceNd Melo MCBd, 2009, REV SBPH, V12, P99eng
hcfmusp.relation.referenceOlesen TB, 2019, LANCET ONCOL, V20, P145, DOI 10.1016/S1470-2045(18)30682-Xeng
hcfmusp.relation.referencePaner GP, 2018, EUR UROL, V73, P560, DOI 10.1016/j.eururo.2017.12.018eng
hcfmusp.relation.referenceParkin DM, 2010, INT J CANCER, V127, P2918, DOI 10.1002/ijc.25517eng
hcfmusp.relation.referencePow-Sang Mariela R, 2002, Cancer Control, V9, P305eng
hcfmusp.relation.referencePrue G, 2017, ORAL DIS, V23, P726, DOI 10.1111/odi.12562eng
hcfmusp.relation.referenceReddy JP, 2017, BJU INT, V119, P591, DOI 10.1111/bju.13686eng
hcfmusp.relation.referenceRubin MA, 2001, AM J PATHOL, V159, P1211, DOI 10.1016/S0002-9440(10)62506-0eng
hcfmusp.relation.referenceSAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980eng
hcfmusp.relation.referenceSalvioni R, 2009, PENILE CANC, P677eng
hcfmusp.relation.referenceSchabath MB, 2011, CANC EPIDEMIOLOGY PReng
hcfmusp.relation.referenceScheiner MA, 2008, INT BRAZ J UROL, V34, P467, DOI 10.1590/S1677-55382008000400009eng
hcfmusp.relation.referenceSchiffman M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.86eng
hcfmusp.relation.referenceSenba M, 2006, J MED VIROL, V78, P1341, DOI 10.1002/jmv.20703eng
hcfmusp.relation.referenceSoufir N, 2007, BRIT J DERMATOL, V156, P448, DOI 10.1111/j.1365-2133.2006.07604.xeng
hcfmusp.relation.referenceSpiess PE, 2016, CA-CANCER J CLIN, V66, P482, DOI 10.3322/caac.21354eng
hcfmusp.relation.referenceStratton KL, 2016, ONCOLOGY-NY, V30, P245eng
hcfmusp.relation.referenceSzostek S, 2009, ACTA BIOCHIM POL, V56, P337eng
hcfmusp.relation.referenceTang DH, 2015, J UROLOGY, V193, P519, DOI 10.1016/j.juro.2014.08.120eng
hcfmusp.relation.referenceTorres KL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201262eng
hcfmusp.relation.referenceVeo CAR, 2015, TUMOR BIOL, V36, P5399, DOI 10.1007/s13277-015-3205-9eng
hcfmusp.relation.referenceYoung LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556eng
hcfmusp.relation.referenceZargar-Shoshtari K, 2016, CLIN GENITOURIN CANC, V14, P346, DOI 10.1016/j.clgc.2015.12.019eng
dc.description.indexMEDLINEeng
hcfmusp.citation.scopus2-
hcfmusp.scopus.lastupdate2022-08-12-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/Outros
Outros departamentos - FM/Outros

Artigos e Materiais de Revistas Científicas - LIM/52
LIM/52 - Laboratório de Virologia

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_MARTINS_Presence_of_HPV_with_overexpression_of_p16INK4a_protein_2020.PDFpublishedVersion (English)1.12 MBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.